WO2001032646A2 - Sulfonamide derivatives - Google Patents
Sulfonamide derivatives Download PDFInfo
- Publication number
- WO2001032646A2 WO2001032646A2 PCT/EP2000/010911 EP0010911W WO0132646A2 WO 2001032646 A2 WO2001032646 A2 WO 2001032646A2 EP 0010911 W EP0010911 W EP 0010911W WO 0132646 A2 WO0132646 A2 WO 0132646A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- description
- compound
- group
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00974509A EP1228066A2 (en) | 1999-11-05 | 2000-11-02 | Sulfonamide derivatives |
JP2001534797A JP2003513085A (en) | 1999-11-05 | 2000-11-02 | New compound |
AU12787/01A AU1278701A (en) | 1999-11-05 | 2000-11-02 | Novel compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9926302.2 | 1999-11-05 | ||
GBGB9926302.2A GB9926302D0 (en) | 1999-11-05 | 1999-11-05 | Novel compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001032646A2 true WO2001032646A2 (en) | 2001-05-10 |
WO2001032646A3 WO2001032646A3 (en) | 2001-12-27 |
Family
ID=10864071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/010911 WO2001032646A2 (en) | 1999-11-05 | 2000-11-02 | Sulfonamide derivatives |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1228066A2 (en) |
JP (1) | JP2003513085A (en) |
AU (1) | AU1278701A (en) |
GB (1) | GB9926302D0 (en) |
WO (1) | WO2001032646A2 (en) |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002100822A1 (en) | 2001-06-11 | 2002-12-19 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
WO2003037887A1 (en) * | 2001-11-01 | 2003-05-08 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
WO2003039547A1 (en) | 2001-11-09 | 2003-05-15 | Biovitrum Ab | Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake |
WO2003068752A1 (en) * | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | Benzenesulfonamide derivatives as antipsychotic agents |
WO2003068751A1 (en) * | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5-ht6 receptor affinity for the reatment of cns disorders |
WO2004000828A1 (en) * | 2002-06-20 | 2003-12-31 | Biovitrum Ab | New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |
WO2004031181A1 (en) * | 2002-10-07 | 2004-04-15 | Glaxo Group Limited | Sulfonamide derivatives as antipsychotic agents |
US6825202B2 (en) | 2001-08-10 | 2004-11-30 | Syntex (U.S.A.) Llc | Arylsulfonyl derivatives with 5-HT6 receptor affinity |
WO2005021530A1 (en) * | 2003-08-29 | 2005-03-10 | Glaxo Group Limited | 8- (1-piperazinyl)- quinoline derivatives and their use in the treatment of cns disorders |
JP2005517705A (en) * | 2002-02-13 | 2005-06-16 | グラクソ グループ リミテッド | Benzenesulfonamide derivatives and their use as dopamine D3 and D2 receptor ligands |
WO2005058858A1 (en) * | 2003-12-19 | 2005-06-30 | Biovitrum Ab | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |
US6939885B2 (en) | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
JP2005533747A (en) * | 2002-02-05 | 2005-11-10 | ノボ ノルディスク アクティーゼルスカブ | Novel aryl and heteroaryl piperazines |
JP2005536551A (en) * | 2002-06-20 | 2005-12-02 | ビオヴィトルム・アクチボラゲット | Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
WO2006062481A1 (en) * | 2004-12-09 | 2006-06-15 | Biovitrum Ab | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
US7084156B2 (en) | 2001-11-27 | 2006-08-01 | Merck & Co., Inc. | 2-Aminoquinoline compounds |
WO2007004960A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer’s desease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson’s disease |
WO2007004959A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson's disease |
CN1315809C (en) * | 2002-03-27 | 2007-05-16 | 葛兰素集团有限公司 | Quinoline derivatives and their use as 5-HT6 ligands |
US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
US7262192B2 (en) | 2003-04-29 | 2007-08-28 | Pfizer Inc. | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors |
EP1837332A1 (en) * | 2006-03-23 | 2007-09-26 | Laboratorios Del Dr. Esteve, S.A. | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments |
WO2007108744A2 (en) * | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators |
WO2007108743A2 (en) * | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators ii |
EP1897881A2 (en) | 2002-06-20 | 2008-03-12 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
US7462640B2 (en) | 2003-07-30 | 2008-12-09 | Laboratorios Del Dr. Esteve S.A. | Indol-6yl sulfonamide derivatives, their preparation and their use as 5-HT-6 as modulators |
US7569572B2 (en) | 2004-04-07 | 2009-08-04 | Pfizer Inc | Pyrazolo[4,3-D]pyrimidines |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
EP2116547A1 (en) * | 2008-05-09 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands |
WO2010032258A1 (en) | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Aryl sulfonamide amine compounds and their use as 5-ht6 ligands |
US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
US7820675B2 (en) | 2003-12-19 | 2010-10-26 | Biovitrum Ab | Benzofuran compounds |
US7923566B2 (en) | 2005-08-16 | 2011-04-12 | Suven Life Sciences Limited | Alternative process for the preparation of losartan |
US7960374B2 (en) | 2006-10-30 | 2011-06-14 | Proximagen Limited | Tricyclic compounds, compositions, and methods useful in the treatment or prophylaxis of 5-HT6 receptor-related disorders |
US7964627B2 (en) | 2007-10-26 | 2011-06-21 | Suven Life Sciences Limited | Amino arylsulfonamide compounds and their use as 5-HT6 ligands |
WO2011083487A1 (en) | 2010-01-05 | 2011-07-14 | Suven Life Sciences Limited | Sulfone compounds as 5-ht6 receptor ligands |
US7998981B2 (en) | 2005-08-12 | 2011-08-16 | Suven Life Sciences Limited | Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands |
US7999109B2 (en) | 2002-05-24 | 2011-08-16 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
US8003670B2 (en) | 2007-05-03 | 2011-08-23 | Suven Life Sciences Limited | Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands |
US8097643B2 (en) | 2003-07-30 | 2012-01-17 | Laboratorios Del Dr. Esteve S. A. | Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
US8344001B2 (en) | 2007-06-11 | 2013-01-01 | High Point Pharmaceuticals, Llc | Heterocyclic H3 antagonists |
US8378097B2 (en) | 2006-05-29 | 2013-02-19 | High Point Pharmaceuticals, Llc | 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist |
US8470830B2 (en) | 2007-01-08 | 2013-06-25 | Suven Life Sciences Limited | 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands |
US8501739B2 (en) | 2005-07-04 | 2013-08-06 | High Point Pharmaceuticals, Llc | Medicaments |
US9745270B2 (en) | 2008-10-28 | 2017-08-29 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US9775829B2 (en) | 2003-07-22 | 2017-10-03 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US9808455B2 (en) | 2007-12-12 | 2017-11-07 | Axovant Sciences Gmbh | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
US9840482B2 (en) | 2014-04-19 | 2017-12-12 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US10059691B2 (en) | 2008-04-02 | 2018-08-28 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1676841A1 (en) * | 2004-12-30 | 2006-07-05 | Esteve Laboratorios Dr. Esteve S.A. | Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments |
DE102007042154A1 (en) * | 2007-09-05 | 2009-03-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Arylsulfonylaminomethyphosphonsäure derivatives, their preparation and their use as medicaments |
CN101952278A (en) * | 2008-02-15 | 2011-01-19 | 弗·哈夫曼-拉罗切有限公司 | 3-alkyl-piperazine derivatives and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021619A1 (en) * | 1993-03-16 | 1994-09-29 | Pfizer Inc. | Naphthalene derivatives |
WO1998027081A1 (en) * | 1996-12-19 | 1998-06-25 | Smithkline Beecham Plc | Sulphonamide derivatives, process for their preparation, and their use as medicaments |
-
1999
- 1999-11-05 GB GBGB9926302.2A patent/GB9926302D0/en not_active Ceased
-
2000
- 2000-11-02 JP JP2001534797A patent/JP2003513085A/en not_active Withdrawn
- 2000-11-02 WO PCT/EP2000/010911 patent/WO2001032646A2/en not_active Application Discontinuation
- 2000-11-02 AU AU12787/01A patent/AU1278701A/en not_active Abandoned
- 2000-11-02 EP EP00974509A patent/EP1228066A2/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021619A1 (en) * | 1993-03-16 | 1994-09-29 | Pfizer Inc. | Naphthalene derivatives |
WO1998027081A1 (en) * | 1996-12-19 | 1998-06-25 | Smithkline Beecham Plc | Sulphonamide derivatives, process for their preparation, and their use as medicaments |
Non-Patent Citations (2)
Title |
---|
BROMIDGE ET AL: "5-Chloro-N-(4-methoxy-3-piperazin-1-yl-ph enyl)-3-methyl-2-benzothioph enesulfonamide(SB-271046): A Potent, Selective, and Orally Bioavailable5-HT6 Receptor Antagonist" JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 42, no. 2, 28 January 1999 (1999-01-28), pages 202-205, XP002109186 * |
SLEIGHT ET AL: "The 5-hydroxytryptamine-6 receptor: localisation and function" EXPERT OPINION ON THERAPEUTIC PATENTS,GB,ASHLEY PUBLICATIONS, vol. 8, no. 10, 1 October 1998 (1998-10-01), pages 1217-1224, XP002093843 * |
Cited By (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA008476B1 (en) * | 2001-06-11 | 2007-06-29 | Биовитрум Аб | Substituted sulfonamide compounds, process for their use as medicaments for the treatment of cns disorders, obesity and type ii diabetes |
WO2002100822A1 (en) | 2001-06-11 | 2002-12-19 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
US7572787B2 (en) | 2001-06-11 | 2009-08-11 | Biovitrum Ab | Substituted naphthalene sulfonamides |
US7144883B2 (en) | 2001-06-11 | 2006-12-05 | Biovitrum Ab | Bicyclic sulfonamide compounds |
JP2004536080A (en) * | 2001-06-11 | 2004-12-02 | ビオヴィトルム・アクチボラゲット | Substituted sulfonamide compounds, their use as medicaments for the treatment of CNS disorders, obesity and type II diabetes |
KR100889718B1 (en) | 2001-06-11 | 2009-03-23 | 바이오비트럼 에이비(피유비엘) | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ? diabetes |
KR100888906B1 (en) * | 2001-06-11 | 2009-03-16 | 바이오비트럼 에이비(피유비엘) | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ⅱ diabetes |
US6825202B2 (en) | 2001-08-10 | 2004-11-30 | Syntex (U.S.A.) Llc | Arylsulfonyl derivatives with 5-HT6 receptor affinity |
WO2003037887A1 (en) * | 2001-11-01 | 2003-05-08 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
WO2003039547A1 (en) | 2001-11-09 | 2003-05-15 | Biovitrum Ab | Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake |
US7084156B2 (en) | 2001-11-27 | 2006-08-01 | Merck & Co., Inc. | 2-Aminoquinoline compounds |
JP2005533747A (en) * | 2002-02-05 | 2005-11-10 | ノボ ノルディスク アクティーゼルスカブ | Novel aryl and heteroaryl piperazines |
JP2005522452A (en) * | 2002-02-13 | 2005-07-28 | グラクソ グループ リミテッド | 7-Arylsulfonamide-2,3,4,5-tetrahydro-1H-benzo'diazepine derivatives having 5-HT6 receptor affinity for the treatment of CNS diseases |
JP2005526724A (en) * | 2002-02-13 | 2005-09-08 | グラクソ グループ リミテッド | Benzenesulfonamide derivatives as antipsychotic agents |
JP2005517705A (en) * | 2002-02-13 | 2005-06-16 | グラクソ グループ リミテッド | Benzenesulfonamide derivatives and their use as dopamine D3 and D2 receptor ligands |
WO2003068752A1 (en) * | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | Benzenesulfonamide derivatives as antipsychotic agents |
WO2003068751A1 (en) * | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5-ht6 receptor affinity for the reatment of cns disorders |
CN1315809C (en) * | 2002-03-27 | 2007-05-16 | 葛兰素集团有限公司 | Quinoline derivatives and their use as 5-HT6 ligands |
US8236947B2 (en) | 2002-03-27 | 2012-08-07 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US7977337B2 (en) | 2002-03-27 | 2011-07-12 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US7601837B2 (en) | 2002-03-27 | 2009-10-13 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US7452888B2 (en) | 2002-03-27 | 2008-11-18 | Glaxo Group Limited | Quinoline derivatives and their use as 5-ht6 ligands |
US7799774B2 (en) | 2002-03-27 | 2010-09-21 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US7999109B2 (en) | 2002-05-24 | 2011-08-16 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
US8030517B2 (en) | 2002-05-24 | 2011-10-04 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
US9035096B2 (en) | 2002-05-24 | 2015-05-19 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
EP1897876A2 (en) | 2002-06-20 | 2008-03-12 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
JP2005536551A (en) * | 2002-06-20 | 2005-12-02 | ビオヴィトルム・アクチボラゲット | Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
SG156524A1 (en) * | 2002-06-20 | 2009-11-26 | Biovitrum Ab Publ | New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |
WO2004000828A1 (en) * | 2002-06-20 | 2003-12-31 | Biovitrum Ab | New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |
EA011581B1 (en) * | 2002-06-20 | 2009-04-28 | Биовитрум Аб (Пабл) | Heterocyclic compounds useful for the treatment of obesity and cns disorders |
EP1897876A3 (en) * | 2002-06-20 | 2009-03-18 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
JP4754821B2 (en) * | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
US7943639B2 (en) | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
EA008835B1 (en) * | 2002-06-20 | 2007-08-31 | Биовитрум Аб | Substituted sulfone and sulfonamides and pharmaceutical compositions based thereon useful for the treatment of obesity, type ii diabetes cns disorders |
EP1897881A2 (en) | 2002-06-20 | 2008-03-12 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
US7122538B2 (en) | 2002-10-07 | 2006-10-17 | Glaxo Group Limited | Sulfonamide derivatives as antipsychotic agents |
WO2004031181A1 (en) * | 2002-10-07 | 2004-04-15 | Glaxo Group Limited | Sulfonamide derivatives as antipsychotic agents |
US6939885B2 (en) | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
US9890148B2 (en) | 2002-11-18 | 2018-02-13 | Chemocentryx, Inc. | Aryl sulfonamides |
US8642808B2 (en) | 2002-11-18 | 2014-02-04 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
US10364240B2 (en) | 2002-11-18 | 2019-07-30 | ChemoCentryx. Inc. | Aryl sulfonamides |
US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
US7335653B2 (en) | 2002-11-18 | 2008-02-26 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
US8211896B2 (en) | 2002-11-18 | 2012-07-03 | Chemocentryx, Inc. | Aryl sulfonamides |
US7582661B2 (en) | 2002-11-18 | 2009-09-01 | Chemocentryx, Inc. | Aryl sulfonamides |
US7262192B2 (en) | 2003-04-29 | 2007-08-28 | Pfizer Inc. | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors |
US9775829B2 (en) | 2003-07-22 | 2017-10-03 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US8097643B2 (en) | 2003-07-30 | 2012-01-17 | Laboratorios Del Dr. Esteve S. A. | Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
US7462640B2 (en) | 2003-07-30 | 2008-12-09 | Laboratorios Del Dr. Esteve S.A. | Indol-6yl sulfonamide derivatives, their preparation and their use as 5-HT-6 as modulators |
WO2005021530A1 (en) * | 2003-08-29 | 2005-03-10 | Glaxo Group Limited | 8- (1-piperazinyl)- quinoline derivatives and their use in the treatment of cns disorders |
US8097621B2 (en) | 2003-11-24 | 2012-01-17 | Pfizer Inc. | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
US7820675B2 (en) | 2003-12-19 | 2010-10-26 | Biovitrum Ab | Benzofuran compounds |
WO2005058858A1 (en) * | 2003-12-19 | 2005-06-30 | Biovitrum Ab | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |
EA010298B1 (en) * | 2003-12-19 | 2008-08-29 | Биовитрум Аб (Пабл) | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-htreceptor-related disorder |
US7569572B2 (en) | 2004-04-07 | 2009-08-04 | Pfizer Inc | Pyrazolo[4,3-D]pyrimidines |
WO2006062481A1 (en) * | 2004-12-09 | 2006-06-15 | Biovitrum Ab | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
US8846677B2 (en) | 2005-07-04 | 2014-09-30 | High Point Pharmaceuticals, Llc | Medicaments |
US8501739B2 (en) | 2005-07-04 | 2013-08-06 | High Point Pharmaceuticals, Llc | Medicaments |
WO2007004960A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer’s desease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson’s disease |
WO2007004959A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson's disease |
US7998981B2 (en) | 2005-08-12 | 2011-08-16 | Suven Life Sciences Limited | Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands |
US7923566B2 (en) | 2005-08-16 | 2011-04-12 | Suven Life Sciences Limited | Alternative process for the preparation of losartan |
WO2007108744A2 (en) * | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators |
WO2007108743A2 (en) * | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators ii |
WO2007108743A3 (en) * | 2006-03-17 | 2007-11-15 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators ii |
WO2007108744A3 (en) * | 2006-03-17 | 2007-11-15 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators |
WO2007107373A1 (en) | 2006-03-23 | 2007-09-27 | Laboratorios Del Dr. Esteve S.A. | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments |
EP1837332A1 (en) * | 2006-03-23 | 2007-09-26 | Laboratorios Del Dr. Esteve, S.A. | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments |
US8378097B2 (en) | 2006-05-29 | 2013-02-19 | High Point Pharmaceuticals, Llc | 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist |
US7960374B2 (en) | 2006-10-30 | 2011-06-14 | Proximagen Limited | Tricyclic compounds, compositions, and methods useful in the treatment or prophylaxis of 5-HT6 receptor-related disorders |
US8470830B2 (en) | 2007-01-08 | 2013-06-25 | Suven Life Sciences Limited | 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands |
US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
US8003670B2 (en) | 2007-05-03 | 2011-08-23 | Suven Life Sciences Limited | Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands |
US8344001B2 (en) | 2007-06-11 | 2013-01-01 | High Point Pharmaceuticals, Llc | Heterocyclic H3 antagonists |
US7964627B2 (en) | 2007-10-26 | 2011-06-21 | Suven Life Sciences Limited | Amino arylsulfonamide compounds and their use as 5-HT6 ligands |
US9808455B2 (en) | 2007-12-12 | 2017-11-07 | Axovant Sciences Gmbh | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
US10059691B2 (en) | 2008-04-02 | 2018-08-28 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
US10787437B2 (en) | 2008-04-02 | 2020-09-29 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
EP2116547A1 (en) * | 2008-05-09 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands |
WO2009135925A1 (en) * | 2008-05-09 | 2009-11-12 | Laboratorios Del Dr. Esteve, S.A. | Substituted n-imidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
US8404720B2 (en) | 2008-09-17 | 2013-03-26 | Suven Life Sciences Limited | Aryl sulfonamide amine compounds and their use as 5-HT6 ligands |
WO2010032258A1 (en) | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Aryl sulfonamide amine compounds and their use as 5-ht6 ligands |
US9745270B2 (en) | 2008-10-28 | 2017-08-29 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
WO2011083487A1 (en) | 2010-01-05 | 2011-07-14 | Suven Life Sciences Limited | Sulfone compounds as 5-ht6 receptor ligands |
US9840482B2 (en) | 2014-04-19 | 2017-12-12 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US11304932B2 (en) | 2015-07-15 | 2022-04-19 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
Also Published As
Publication number | Publication date |
---|---|
JP2003513085A (en) | 2003-04-08 |
WO2001032646A3 (en) | 2001-12-27 |
AU1278701A (en) | 2001-05-14 |
GB9926302D0 (en) | 2000-01-12 |
EP1228066A2 (en) | 2002-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001032646A2 (en) | Sulfonamide derivatives | |
US7799774B2 (en) | Quinoline derivatives and their use as 5-HT6 ligands | |
EP1497291B1 (en) | Quinoline and aza-indole derivatives and their use as 5-ht6 ligands | |
US20040242589A1 (en) | 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders | |
EP1730112B1 (en) | 3-((hetero)arylsulfonyl)-8'[ (aminoalkyl)oxy]quinolines as 5-ht6 receptor antagonists for the treatment of cns disorders | |
JP2002504484A (en) | New compound | |
US7439244B2 (en) | Quinoline compounds and pharmeceutical compositions containing them | |
US7439243B2 (en) | Piperazinyl-quinoline derivatives useful for the treatment of CNS disorders | |
EP1660483B1 (en) | 8-(1-piperazinyl)-quinoline derivatives and their use in the treatment of cns disorders | |
US20040053956A1 (en) | Isoquinoline derivatives useful in the treatment of cns disorders | |
Ahmed et al. | Quinoline derivatives and their use as 5-HT6 ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000974509 Country of ref document: EP |
|
ENP | Entry into the national phase in: |
Ref country code: JP Ref document number: 2001 534797 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000974509 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000974509 Country of ref document: EP |